177Lu-PSMA and 177Lu-DOTATATE Therapy in a Patient With Metastatic Castration-Resistant Prostate Cancer and Neuroendocrine Differentiation

被引：18
|
作者：
Assadi, Majid [1 ]
Pirayesh, Elahe [2 ]
Rekabpour, Seyed Javad [3 ]
Zohrabi, Farshad [4 ]
Jafari, Esmail [1 ]
Nabipour, Iraj [5 ]
Esmaili, Abdolhamid [6 ]
Amini, Abdullatif [7 ]
Ahmadzadehfar, Hojjat [8 ]
机构：
[1] Bushehr Univ Med Sci, Bushehr Med Univ Hosp, Persian Gulf Nucl Med Res Ctr, Dept Mol Imaging & Radionuclide Therapy,Fac Med, Bushehr, Iran
[2] Shahid Beheshti Univ Med Sci, Shohada & Tajrish Med Ctr, Dept Nucl Med, Tehran, Iran
[3] Bushehr Med Univ Hosp, Dept Oncol, Bushehr, Iran
[4] Bushehr Med Univ Hosp, Dept Urol, Bushehr, Iran
[5] Bushehr Med Univ Hosp, Dept Internal Med, Div Endocrinol, Bushehr, Iran
[6] Bushehr Med Univ Hosp, Dept Pathol, Bushehr, Iran
[7] Bushehr Univ Med Sci, Dept Cardiol, Bushehr Heart Med Ctr, Bushehr, Iran
[8] Univ Hosp Bonn, Dept Nucl Med, Bonn, Germany
来源：
CLINICAL NUCLEAR MEDICINE | 2019年 / 44卷 / 12期
关键词：
prostate cancer; neuroendocrine differentiation; Lu-177-PSMA; Lu-177-DOTATATE; GA-68-PSMA; MEDICINE;
D O I：
10.1097/RLU.0000000000002824
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
We presented a promising result of radionuclide therapy using Lu-177-PSMA and Lu-177-DOTATATE in a patient with prostatic adenocarcinoma and neuroendocrine differentiation. Functional imaging of somatostatin receptors in patients with metastatic castration-resistant prostate cancer may pave the way toward implementation of novel radionuclide targets for the treatment of this aggressive subtype of prostate cancer.
引用
收藏
页码：978 / 980
页数：3
相关论文
共 50 条
  • [1] Excellent Response to 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in a Patient With Progressive Metastatic Castration-Resistant Prostate Cancer With Neuroendocrine Differentiation After 177Lu-PSMA Therapy
    Liu, Chen
    Liu, Teli
    Zhang, Jingjing
    Baum, Richard P.
    Yang, Zhi
    [J]. CLINICAL NUCLEAR MEDICINE, 2019, 44 (11) : 876 - 878
  • [2] 177Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
    Sanli, Yasemin
    Simsek, Duygu Has
    Sanli, Oner
    Subramaniam, Rathan M.
    Kendi, Ayse Tuba
    [J]. BIOMEDICINES, 2021, 9 (04)
  • [3] Prostate Cancer With Neuroendocrine Differentiation Recurring After Treatment With 177Lu-PSMA A Chance for 177Lu-DOTATATE Therapy?
    Nesari Javan, Farnaz
    Aryana, Kamran
    Askari, Emran
    [J]. CLINICAL NUCLEAR MEDICINE, 2021, 46 (09) : E480 - E482
  • [4] Dual 177Lu-Prostate-Specific Membrane Antigen and 177Lu-DOTATATE Therapy in Metastatic Castration-Resistant Prostate Cancer With Neuroendocrine Differentiation
    Beyhan, Ediz
    Fenercioglu, Ozge Erol
    Sahin, Rahime
    Cermik, Tevfik Fikret
    Ergul, Nurhan
    [J]. CLINICAL NUCLEAR MEDICINE, 2024, 49 (05) : 447 - 448
  • [5] Perspective on 177Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer
    Kwekkeboom, Dik
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (07) : 1002 - 1003
  • [6] High Activity 177Lu-PSMA Therapy Of Metastatic Castration-resistant Prostate Cancer
    Happel, C.
    Kranert, W. T.
    Bockisch, B.
    Groener, D.
    Davis, K. H.
    Wichert, J.
    Stefanova, M.
    Gruenwald, F.
    Sabet, A.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S647 - S648
  • [7] 177Lu-PSMA for Extended Treatment of Metastatic Castration-Resistant Prostate Cancer
    Derlin, Thorsten
    Widjaja, Liam
    Werner, Rudolf A.
    Bengel, Frank M.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (01) : 54 - 58
  • [8] Incorporation Of 177Lu During Care Of 177Lu-PSMA And 177Lu-DOTATATE Therapy Patients
    Happel, C.
    Kranert, W. T.
    Bockisch, B.
    Kratzel, U.
    Baumgarten, J.
    Ngoc, C. Nguyen
    Garayev, E.
    Gruenwald, F.
    Sabet, A.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S842 - S843
  • [9] Predicting outcomes after 177Lu-PSMA therapy in castration-resistant prostate cancer
    Hindie, Elif
    [J]. LANCET ONCOLOGY, 2021, 22 (10): : E425 - E425
  • [10] Advances in 177Lu-PSMA and 225Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
    Ling, Sui Wai
    de Blois, Erik
    Hooijman, Eline
    van der Veldt, Astrid
    Brabander, Tessa
    [J]. PHARMACEUTICS, 2022, 14 (10)
12345